Unlock instant, AI-driven research and patent intelligence for your innovation.

Imidazoimidazoles and triazoles as anti-inflammatory agents

A technology of carbon atoms and alkyl groups, applied in the field of treatment of inflammatory diseases, can solve the problems of lack of selectivity, unsatisfactory therapeutic use of small molecules, lack of specificity, etc.

Inactive Publication Date: 2002-10-02
BOEHRINGER INGELHEIM PHARMA INC
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Said small molecules appear to be unsatisfactory for therapeutic use due to lack of potency, lack of selectivity and lack of specific mechanism of action

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[1060] A solution of amino-ester XIII and 3,5-dichlorophenyl isothiocyanate (1:1 molar ratio) in 1,4-dioxane was heated at 90°C in N2 for 10 hours. The mixture was concentrated to obtain the thiohydantoin derivative XIV. Product use 1 H NMR and mass spectrometer identification.

[1061] With PPh 3 To a solution of (9.0 mmol) in toluene (20 mL) was added azide XV (9.0 mmol) under nitrogen. After stirring at room temperature overnight, thiohydantoin XIV (4.5 mmol) was added. Mixture in N 2 The medium is sealed in a pressure tube and heated at 130-140°C for 3-4 days, concentrated and purified by silica gel chromatography to obtain the product XVI. Product use 1 H NMR and mass spectrometer identification.

[1062] Trifluoroacetic acid (TFA, 5-6 equivalents) is added to the dichloroethane solution containing XVI. The mixture was heated in N2 at 90°C overnight. The residue was placed in EtOAc, and saturated NaHCO 3 Washing, dehydration (Na 2 SO 4 ) And concentration. The residue was pur...

Embodiment 2

[1064] A dichloromethane solution (20 mL) containing compound 1 (1.82 g, 4.04 mmol) was cooled to 0°C and a small amount of N-iodosuccinimide (1.43 g, 6.04 mmol) was added thereto. Pyridine p-toluenesulfonate (100 mg, 0.40 mmol) was added and the mixture was stirred at 0°C for 3 hours, during which time additional N-iodosuccinimide (400 mg, 1.68 mmol) was added to complete the reaction. The mixture was diluted with dichloromethane, with 10% Na 2 SO 3 The solution is washed, dehydrated and concentrated. The residue was purified by silica gel chromatography to obtain a mixture of title compound 2 (1.86 g) and 2a (0.53 g). Product use 1 H NMR and mass spectrometer identification.

[1065] Using more than 2 molar equivalents of N-iodosuccinimide, using the same procedure described above, a single product of diiodide 2a can also be produced from 1. Example 3

Embodiment 3

[1066] A solution of compound 2 (33 mg, 0.0572 mmol) in THF was treated with 2.0 M cyclopentylmagnesium bromide (57 μl, 0.114 mmol) at -30°C in nitrogen. After the mixture was stirred at -30°C for 2 hours, a solution containing tosyl cyanide (70 mg, 0.367 mmol) in THF (0.5 mL) was added. The mixture was stirred at -30°C for 1 hour and at room temperature overnight. Saturated NH 4 The Cl solution was quenched at 0°C. Extraction with EtOAc followed by silica gel chromatography gave compound 3 as a foam (9.5 mg, 35%). Product use 1 H NMR and mass spectrometer identification.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Compounds of formula I for use in the treatment or prevention of inflammatory and immune cell-mediated diseases.

Description

Invention field [0001] The present invention relates to a series of new small molecules, their synthesis and their use in the treatment of inflammatory diseases. Background of the invention [0002] Research in the past decade has explained the molecular changes involved in cell-cell interactions in the body, especially those involving cell movement and activation in the immune system. See, for example, Springer, T. Nature, 1990, 346, 425-434. Cell surface proteins, especially cell adhesion molecules ("CAMs") and "leukocyte integrins", including LFA-1, MAC-1 and gp150.95 (referred to as CD18 / CD11a, CD18 / CD11b and CD18 / CD11c)), they have correspondingly become the subject of medical research and development, and their purpose is to intervene in the process of leukocyte extravasation to the injured site and to different targets. For example, it is currently believed that before the extravasation of leukocytes (which is a mandatory component of the inflammato...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4188A61K31/438A61K31/4439A61K31/496A61K31/506A61K31/519A61K31/5377A61K31/551A61K31/675A61P1/14A61P3/10A61P7/08A61P11/00A61P17/06A61P27/02A61P29/00A61P37/02A61P39/06A61P43/00C07D487/04C07D519/00C07F9/6561C07F9/6571
CPCC07D487/04C07F9/6561C07F9/657181Y02P20/582A61P1/14A61P11/00A61P17/06A61P27/02A61P29/00A61P37/00A61P37/02A61P39/06A61P43/00A61P7/08A61P3/10
Inventor 吴江平特伦斯·A·凯利勒内·M·勒米厄丹尼尔·R·戈德堡乔纳森·E·埃梅格罗纳德·J·索塞克
Owner BOEHRINGER INGELHEIM PHARMA INC